http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2010145158-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-542 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 |
| filingDate | 2009-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2010145158-A |
| titleOfInvention | DERIVATIVES OF OPIORPHIN PEPTIDE AS POTENTIAL INHIBITORS OF ECTOPEPTIDASES PARTICIPATED IN ENCEPHALIN DEGRADATION |
| abstract | 1. The peptide derivative of the formula (I):! ! wherein: ! - ζ represents a hydrogen atom, tyrosine, Y- [linker] - or Zn chelate group such as cysteine, C- [linker] -, N-acetyl-cysteine, N-mercaptoacetyl (HS-CH2-CO-), hydroxamic acid (HO-NH-CO-) or optionally substituted hydroxyquinoline,! - AA1 represents Q or Glp,! - AA2 represents K, R or H, preferably R,! - AA3 is Y, G, N, F or F (X), preferably F or F (X),! - AA4 is P, S or S (OAlk), preferably S or S (OAlk),! - AA5 is K or R, preferably R,! - C- [linker] - means Cys- [NH- (CH2) n-CO] -, where n is an integer between 1 and 20,! - Y- [linker] - means Tyr- [NH- (CH2) n'-CO] -, where n 'is an integer between 1 and 20,! - F (X) means phenylalanine, the phenyl group of which is substituted by one or more halogen atoms,! - S (OAlk) means serine, the hydroxyl group of which is substituted by a linear or branched alkyl group having from 1 to 20 carbon atoms,! - the specified AA1, AA2, AA3, AA4 and AA5 independently can be either in the L-configuration or D-configuration, and any one of AA1, AA2, AA3, AA4 and AA5 may optionally be a β-amino acid, aza-amino acid or β- aza amino acid; ! where, if the peptide derivative contains cysteine, said peptide derivative is optionally a dimer,! provided that the peptide is not QRFSR, QHNPR, QRGPR, YQRFSR or GlpRFSR. ! 2. The peptide derivative according to claim 1 of the formula (II):! ! wherein: ! - ζ8 represents a hydrogen atom or a Zn chelate group such as cysteine, C- [linker] -, N-acetyl-cysteine, N-mercaptoacetyl (HS-CH2-CO-), hydroxamic acid (HO-NH-CO-) or optionally substituted hydroxyquinoline,! - AAa 2 represent |
| priorityDate | 2008-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 59.